Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The HIV-1 envelope glycoprotein structure: nailing down a moving target.

Ward AB, Wilson IA.

Immunol Rev. 2017 Jan;275(1):21-32. doi: 10.1111/imr.12507. Review.

PMID:
28133813
2.

Evolution of B cell analysis and Env trimer redesign.

Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT.

Immunol Rev. 2017 Jan;275(1):183-202. doi: 10.1111/imr.12515. Review.

PMID:
28133805
3.

B-cell responses to HIV infection.

Moir S, Fauci AS.

Immunol Rev. 2017 Jan;275(1):33-48. doi: 10.1111/imr.12502. Review.

PMID:
28133792
4.

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.

Jaworski JP, Vendrell A, Chiavenna SM.

Front Immunol. 2017 Jan 11;7:661. doi: 10.3389/fimmu.2016.00661. Review.

5.

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.

Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, Abdool Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL.

PLoS Pathog. 2017 Jan 11;13(1):e1006074. doi: 10.1371/journal.ppat.1006074.

6.

Progress toward active or passive HIV-1 vaccination.

Escolano A, Dosenovic P, Nussenzweig MC.

J Exp Med. 2017 Jan;214(1):3-16. doi: 10.1084/jem.20161765. Review.

PMID:
28003309
7.

Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.

Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, Piechocka-Trocha A, Walker BD, Chibnik LB, Jost S, Porichis F.

J Int AIDS Soc. 2016 Dec 9;19(1):21136. doi: 10.7448/IAS.19.1.21136.

8.

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.

Zhang Z, Li S, Gu Y, Xia N.

Int J Mol Sci. 2016 Nov 18;17(11). pii: E1901. Review.

9.

Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

VanBlargan LA, Goo L, Pierson TC.

Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010. Review.

PMID:
27784796
10.

HIV-host interactome revealed directly from infected cells.

Luo Y, Jacobs EY, Greco TM, Mohammed KD, Tong T, Keegan S, Binley JM, Cristea IM, Fenyƶ D, Rout MP, Chait BT, Muesing MA.

Nat Microbiol. 2016 Jul;1(7):16068.

11.

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.

Sun M, Li Y, Yuan Z, Lu W, Kang G, Fan W, Li Q.

Arch Virol. 2016 Sep;161(9):2449-55. doi: 10.1007/s00705-016-2942-4.

PMID:
27343044
12.

Maturational characteristics of HIV-specific antibodies in viremic individuals.

Meffre E, Louie A, Bannock J, Kim LJ, Ho J, Frear CC, Kardava L, Wang W, Buckner CM, Wang Y, Fankuchen OR, Gittens KR, Chun TW, Li Y, Fauci AS, Moir S.

JCI Insight. 2016;1(3). pii: e84610.

13.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS.

PLoS Pathog. 2016 Mar 30;12(3):e1005520. doi: 10.1371/journal.ppat.1005520.

14.

Generation of Recombinant Monoclonal Antibodies from Immunised Mice and Rabbits via Flow Cytometry and Sorting of Antigen-Specific IgG+ Memory B Cells.

Starkie DO, Compson JE, Rapecki S, Lightwood DJ.

PLoS One. 2016 Mar 29;11(3):e0152282. doi: 10.1371/journal.pone.0152282.

15.

Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design.

Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E.

J Exp Med. 2016 Apr 4;213(4):469-81. doi: 10.1084/jem.20151960. Review.

16.

Antibody recognition of HIV and dengue glycoproteins.

Krauss IJ.

Glycobiology. 2016 Aug;26(8):813-9. doi: 10.1093/glycob/cww031. Review.

PMID:
26941393
17.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238.

18.

Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures.

Cox KS, Tang A, Chen Z, Horton MS, Yan H, Wang XM, Dubey SA, DiStefano DJ, Ettenger A, Fong RH, Doranz BJ, Casimiro DR, Vora KA.

MAbs. 2016;8(1):129-40. doi: 10.1080/19420862.2015.1109757.

19.

Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Habte HH, Banerjee S, Shi H, Qin Y, Cho MW.

Virology. 2015 Dec;486:187-97. doi: 10.1016/j.virol.2015.09.010.

Supplemental Content

Support Center